How to appeal an Anti-VEGF Injections (Eylea / Lucentis / Avastin) denial
These are among the highest-drug-cost claims in medicine, and denials usually target the J-code drug, the step-therapy sequence, or the injection-plus-imaging bundle, not the injection procedure itself.
Common code: CPT 67028 (intravitreal injection) + J0178 (aflibercept), J2778 (ranibizumab), J9035/J7999 (bevacizumab)Why it gets denied
- Step-therapy requires bevacizumab (Avastin) be tried before Eylea or Lucentis and it wasn't documented
- Prior authorization for the branded agent was missing or lapsed
- Drug units/dosage on the J-code don't reconcile to the vial and get denied or downcoded
- A same-day OCT or the injection is bundled with an office visit
What overturns it
- Document the step-therapy trial and failure, or the medical contraindication to bevacizumab, and pursue the exception
- Obtain or reference the prior auth and tie the auth number to the drug line
- Reconcile billed J-code units to the administered dose and correct waste billing with the JW modifier
- Show the OCT and injection were separately identifiable and support the treatment decision
Worth appealing? A single Eylea claim can exceed $1,800 in drug cost alone, so a denied J-code is money the practice already spent buying the drug. These are high-stakes and highly recoverable with the auth and dosing documentation.
Common questions
How do I appeal an Anti-VEGF Injections (Eylea / Lucentis / Avastin) denial?
These are among the highest-drug-cost claims in medicine, and denials usually target the J-code drug, the step-therapy sequence, or the injection-plus-imaging bundle, not the injection procedure itself. To overturn it: document the step-therapy trial and failure, or the medical contraindication to bevacizumab, and pursue the exception; obtain or reference the prior auth and tie the auth number to the drug line; reconcile billed J-code units to the administered dose and correct waste billing with the JW modifier; show the OCT and injection were separately identifiable and support the treatment decision.
Why do Anti-VEGF Injections (Eylea / Lucentis / Avastin) claims get denied?
Step-therapy requires bevacizumab (Avastin) be tried before Eylea or Lucentis and it wasn't documented; Prior authorization for the branded agent was missing or lapsed; Drug units/dosage on the J-code don't reconcile to the vial and get denied or downcoded; A same-day OCT or the injection is bundled with an office visit.
Is a Anti-VEGF Injections (Eylea / Lucentis / Avastin) denial worth appealing?
A single Eylea claim can exceed $1,800 in drug cost alone, so a denied J-code is money the practice already spent buying the drug. These are high-stakes and highly recoverable with the auth and dosing documentation. You pay 25% only on what's recovered, so there's no cost to working the winnable ones.
See how many Anti-VEGF Injections (Eylea / Lucentis / Avastin) denials you wrote off.
A free assessment shows your real recoverable number. No risk, paid only on what we recover.